# ALX Oncology Q3 2026 Results

> ALX Oncology Holdings reports narrower Q3 2026 loss as clinical trials advance.
- Title: ALX Oncology Q3 2026 Results | Shortify
- Summary: ALX Oncology Holdings reports narrower Q3 2026 loss as clinical trials advance. ALX Oncology Holdings Inc.
- Keywords: alx oncology holdings inc, alxo, earnings, q3 2026, net loss, clinical pipeline, Alphastreet - Earnings Decoded. Market Intelligence Delivered
- URL: https://shortify.news/story/alx-oncology-q3-2026-results
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/alx-oncology-holdings-releases-q3-2026-financial-results
- Author: AlphaStreet Newsdesk
- Published: 2026-11-16T14:49:55+00:00
- Read time: 1 min
- Topics: alx oncology holdings inc, alxo, earnings, q3 2026, net loss, clinical pipeline
## Q3 2026 Financial Results
ALX Oncology Holdings Inc. reported a narrower loss for the third quarter of 2026.
## Net Loss Details
The company posted a net loss of $21.8M for the quarter, translating to a loss of $0.15 per share.
## Improvement from Previous Year
The $0.15 per share loss narrowed 63.4% from the $0.41 loss ALX Oncology recorded in the third quarter of 2025.
## Key takeaway

ALX Oncology Holdings Inc. reported a narrower net loss of $0.15 per share in Q3 2026, down 63.4% from Q3 2025.

---

Summary: Shortify — https://shortify.news/story/alx-oncology-q3-2026-results
Reporting: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/alx-oncology-holdings-releases-q3-2026-financial-results

When you use this summary, link the Shortify URL for the summary and credit the reporting to its newsroom.